Navigation Links
Sanofi-aventis Announces Good First-quarter 2009 Performance
Date:4/29/2009

main growth driver, with net sales up 15.8%.

In the United States, the end of commercialization of Copaxone(R) by sanofi-aventis effective April 1, 2008 resulted in a 5.1% drop in net sales at constant exchange rates. On a constant structure basis and at constant exchange rates, net sales rose by 5.1% on the back of an excellent performance from Lantus(R), despite destocking of some products in distribution channels.

Net sales for Other Countries region rose by 7.6%, boosted by the performance of the Human Vaccines business and by Japan. Growth in the Asia-Pacific region was 12.8%, boosted by a fine performance in China (29.8% growth). Net sales in Japan were up 13.8% at euro 510 million, driven by the success of Plavix(R), Myslee(R) and Allegra(R). Latin America posted growth of 5.7%. The Vaccines business achieved growth of 16.8% in the Other Countries region, to euro 216 million.

First-quarter 2009 financial results

Adjusted income statement excluding selected items

Sanofi-aventis generated first-quarter net sales of euro 7,107 million, an increase of 2.5% on a reported basis. Other revenues were 21.1% higher, driven by a good performance from Plavix(R) in the United States and the appreciation of the dollar.

Gross profit totaled euro 5,684 million, up 6.6% (2.4% at constant exchange rates). The ratio of cost of sales to net sales improved by 2.4 points to 24.8% due to a favorable product mix (amplified by the rise in the dollar), and to the end of the commercialization of Copaxone(R) in North America.

Research and development expenses were up 5.8% (2.8% at constant exchange rates) at euro 1,152 million. This figure includes provisions of euro 54 million associated with the discontinuation of some projects following the recently-completed review of the R&D portfolio.

Selling and gene
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Sanofi-Aventis and Roche/Chugais Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
2. Sanofi-aventis Affirms Its Commitment to Partnering with Local Communities to Improve Hispanic and African American Health
3. Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States
4. Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer
5. Sanofi-aventis Partners with the Hispanic Community in Miami to Increase Health Awareness, Access to Resources and Help Improve Patient Care
6. Sanofi-aventis Partners with the Hispanic Community in San Antonio to Increase Health Awareness, Access to Resources and Help Improve Patient Care
7. Sanofi-aventis Delivers 2008 Results Above Guidance
8. Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
9. Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
10. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
11. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Fla. (PRWEB) July 28, 2014 Sarasota-based ... Florida’s Best Companies To Work For. Still headquartered in ... is the only Florida-domiciled company in the top ten ... Best Companies list appears in the August issue of ... medium and large employer categories. Ranked #7 for 2014, ...
(Date:7/28/2014)... The American Society of ... engaged in the field of organ transplantation, today ... Immunology Research Network (TIRN), a professional network ... modern organ transplantation continues to diversify, AST determined ... more opportunities for physicians, scientists and researchers to ...
(Date:7/28/2014)... HIV research findings made possible by a test developed ... Pharmaceutical Sciences (CU School of Pharmacy), AURORA, Colo (July 28, ... in the Colorado Antiviral Pharmacology Laboratory at the CU ... HIV prevention drug called Truvada (a combination of tenofovir/emtricitabine), ... , A study presented during the AIDS 2014 ...
(Date:7/28/2014)... Drorit Silverman, a professional bodybuilder and ... raise investment capital through her crowd funding camping to ... United States. , According to a statement released by ... provide a great window of opportunity for investors like ... addition to this, Silverman looks at the 24/7 fitness ...
(Date:7/28/2014)... "Fist bumping" transmits significantly fewer bacteria than either ... expectation of hand-to-hand contact between patients and clinicians, ... issue of the American Journal of Infection ... for Professionals in Infection Control and Epidemiology (APIC). ... Biological, Environmental, and Rural Sciences at Aberystwyth University ...
Breaking Medicine News(10 mins):Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 2Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Fist-bumping beats germ-spreading handshake, study reports 2
... Benefit from Fosamax, Boniva, Zometa does not apply to obese ... types of bone-building drugs used to prevent and treat osteoporosis ... research. , The study, which included 6,000 Wisconsin women aged ... such as Fosamax, Boniva and Zometa for more than two ...
... ... wireless fitness sector. , ... Cochrane, Alberta (PRWEB) March 5, 2010 -- ANT Wireless ("ANT" www.thisisant.com ), ... ANT+ Alliance. A noted leader in the design and manufacturing of sport ...
... Twelve children ... attorneys like David Perecman understand frustration of the families. , ... New York, NY (PRWEB) March 5, 2010 -- The U.S. ... by Maclaren. However, as reported by the New York Post , this was ...
... ... partnership with leading SolidWorks and Agile PLM reseller GoEngineer to distribute DesignState Enterprise PDM ... to manage engineering data and collaborate across the enterprise with Oracle,s powerful Agile ... ...
... ... in the U.S., according to the Centers for Disease Control (CDC). , ... Charleston, SC (PRWEB) March 5, ... Infections (HAIs) and they have generated much attention over the last decade. Studies have ...
... ... Mikel J. Harry, the world renowned co-creator of Six Sigma and national ... achievement to the point of breakthrough – and beyond. In this ... can envision, plan and achieve extraordinary things. The Great Discovery® is a ...
Cached Medicine News:Health News:Certain Bone Drugs May Lower Breast Cancer Risk 2Health News:Suunto Joins ANT+ Interoperable Ecosystem 2Health News:Suunto Joins ANT+ Interoperable Ecosystem 3Health News:Defective Child Product Recall Involves New York Personal Injury Attorneys 2Health News:Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState 2Health News:Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState 3Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 2Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 3Health News:Co-Creator of Six Sigma Unveils “The Great Discovery” ... the 4th Generation of Six Sigma 2
(Date:7/28/2014)... luglio 2014 ResMed (NYSE: RMD ... la cura dei disturbi respiratori del sonno (SDB) e ... permanente in Germania contro il produttore Taiwanese di dispositivi ... di apparecchiature da indossare in testa, che violano i ... 220. La sentenza della Corte Regionale Distrettuale di ...
(Date:7/28/2014)... OXFORD, England , July 28, 2014 ... bekannt, dass Albion Ventures 2,5 Millionen £ ... Kundenautomatisierungsmanagement in der Konsumgüter-, Gesundheits-, Pharma- und ... Shackleton Ventures.      (Photo: ... letzten 18 Monaten hat OmPrompt sein beschleunigtes ...
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
Breaking Medicine Technology:ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2
... 2012  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... March 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c ... loss from continuing operations of $513,000, or $0.16 per ... compared to income from continuing operations of $909,000, or ...
... OAKS, Calif., May 4, 2012  Amgen (NASDAQ: AMGN ... Wednesday, May 9, 2012, at the Four Seasons Hotel, Chicago, ... vice president of Investor Relations at Amgen, will present. Live ... Calendar on Amgen,s website, www.amgen.com , under Investors. ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 2Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 3Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 4Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 5Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 6Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 7Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 8
... I Direct to High Res SSP kits provide high ... tray. Locus specific typing on a single tray reduces ... Straight from genomic DNA to high resolution results, no ... typing with a single tray , Unique reaction pattern ...
... built-in bags as in a suspension file system, ... contacting the ethylene glycol and without having to ... easy handling and maximum surface freezing concurrently with ... relatively hot air under the lid does not ...
... 8624 is UL Listed, CSA ... Plasma Freezers safely store single ... cryoprecipitate. Recorders are standard. Cold ... (12.7cm) of foamed-inplace polyurethane insulation ...
... A small self-contained freezer complying with ... blood plasma. External finish is grey colorbond ... assisted lid opening to a 40-litre capacity ... an effective single gasket contacting a heated ...
Medicine Products: